Protocol Ledger

NCT04188509 · Phase III · TERMINATED

Open-Label Extension of Voxelotor

Interventional Phase III clinical trial protocol NCT04188509 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-18 Enrollment: 162 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04188509
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)162 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04188509
Protocol FieldVerified Registry Value
NCT IdentifierNCT04188509
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment162 participants (ACTUAL)
Registered Start Date2019-11-18
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04188509
Hospital Research SiteLocationSite Profile
Children's National Medical CenterWashington D.C, DCOpen Hospital Dossier ->
Northwestern Memorial and Lurie Cancer CenterChicago, ILOpen Hospital Dossier ->
UPMC Children's Hospital of PittsburghPittsburgh, PAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI